The FDA recently approved Abon Pharmaceuticals' Abbreviated New Drug Application for its Clofarabine Injection as a treatment for pediatric patients who suffer from relapsed or refractory acute lymphoblastic leukemia, a deadly cancer disease.
"This product launch is a significant milestone for Abon" Abon Pharmaceuticals President and CEO Salah Ahmed said.
The 20 mg/20 mL drug is offered as a single-use vial and was developed to treat patients who range from 1 to 21 years of age. Thus far, this drug has acquired over $67 million in sales and has been launched as First-to-Market for CLOLAR.
This is Abon Pharmaceuticals' third product to receive a patent. Addiitonally, five more patents are pending on Abon Pharmaceuticals drugs.
Alerts Sign-up